Skip to main content
OpenTrials
Completed

NCT Number: NCT05651685

Treatment Recommendations for Patients With ADHD TDApp2

The purpose of this study is to compare the recommendations made by TDApp2 with those by relevant clinical practice guidelines in children/adolescents with ADHD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Attention Deficit Disorder With Hyperactivity Attention Deficit and Disruptive Behavior Disorders Mental Disorders Neurodevelopmental Disorders

Age range

6 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut d'Assitència Sanitària

Salt, Catalonia, Spain

About this study

Clinical practice guidelines (CPG) allow optimizing medical decisions and health care based on the best evidence available. Nevertheless, CPGs have several limitations. First, many GPC are outdated shortly after their publication. Second, CPG recommendations are often not applicable to many patients treated in clinical practice. Most CPGs do not make recommendations for complex patients with comorbidities. Another limitation is that patients involvement in CPGs development is still poor. To overcome these limitations, study investigators developed TDApp, an eHealth tool to formulate decentralized, participatory, individualized and automated pharmacologic treatment recommendations for patients with Attention Deficit Hyperactivity Disorder. TDApp was initially tested in a clinical sample of ADHD patients (https://clinicaltrials.gov/ct2/show/NCT04228094), but, as it was the first human use, treatment recommendations were kept hidden to the clinicians until the last patient enrolled completed study participation. This safeguard was implemented to avoid potential misguidance. After completing this study, the investigators developed a new iteration of TDApp (TDApp2) that can also recommend non-pharmacological interventions.

In this study, the investigators aim to assess TDApp2: an eHealth tool that formulates participatory, participatory, explainatory and automated therapeutic recommendations for patients with Attention Deficit Hyperactivity Disorder. The recommendations made by TDApp2 will be compared with those made by relevant clinical practice guidelines in children/adolescents with ADHD.

A 6-week, one group, open label study will be conducted. Tirty-two children/adolescents aged < 18 yo with ADHD and their parents will use TDApp. The treatment recommendations made by the TDApp2 will be compared to those made by relevant CPG (American Academy of Pediatrics CPG, Canadian ADHD Resource Alliance (CADDRA) GPC, National Institute for Health and Care Excellence (NICE) GPC, the Australian ADHD Professionals Association guideline, and the Spanish GPC). As the study will be carried out in Catalonia (Spain), the primary comparison will be performed vs. the Spanish CPG. Also, TDApp2 recommendations will be compared with the actual treatment prescribed by the clinicians.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 6-17 yo
  • Meeting DSM 5 criteria for ADHD
  • Requiring treatment initiation for ADHD or requiring a treatment change

Exclusion criteria

  • Patients who are receiving treatment for ADHD and who are well controlled with it
  • Patients who do not have a suitable electronic device for TDApp2

Treatment and study plan

Primary outcomes

  1. Treatment recommended

    Time frame: Week 1

    Treatment recommended consists on the treatment recommended to the patient with ADHD by TDApp2 and CPG. The number and type of recommended treatments will be compared.

Secondary outcomes

  1. Pharmacological distance according to the the NbN2R classification

    Time frame: Week 1

    The pharmacological distance corresponds to the number of pharmacological targets and modes of action that are different between two drugs according to the the NbN2R classification. E.g., the pharmacological distance between methylphenidate and atomoxetine is 16 because they are two different chemical entities and their pharmacological targets and modes of action are rather different (methylphenidates acts primarily on the dopamine (DA) neurotransmission and secondarily on the norepinephrine (NE) one, and inhibits the DA and NE transporters and releases DA and NE, while atomoxetine is a selective NE transporter inhibitor). Conversely, as methylphenidate and dexmethylphenidate act on the same pharmacological targets and have the same mode of action their pharmacological distance is 1 because they are 2 different chemical entities although closely related.

    The pharmacological distance ranges 1-26 with higher score denoting a greater pharmacological distance

  2. ADHD symptom severity as assessed by the DSM 5 Attention-Deficit/Hyperactivity Disorder Rating Scale

    Time frame: Baseline and week 6

    ADHD symptom severity assessed with the DSM 5 Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS).

    The DSM 5 ADHD-RS ranges 0-54 with higher score denoting a worse outcome.

  3. Global assessment of severity of illness as assessed by the Clinical Global Impression - Severity of Illness (CGI-S) Scale

    Time frame: Baseline and week 6

    The CGI-S measures symptom severity of patients with mental disorders. CGI ranges 1-7 with higher score denoting a worse outcome.

  4. Sense of coherence as assessed by the Sense of Coherence (SOC)-13 by Antonovsky

    Time frame: Week 1 and week 3

    The degree to which the patient views the world and the individual environment as comprehensible, manageable, and meaningful as assessed by the Sense of Coherence (SOC)-13 by Antonovsky.

  5. Individuals' confidence in their capacity to act in the ways necessary to reach specific goals as assessed by the Bäbler, Schwarzar, and Jerusalem self-efficacy scale

    Time frame: Week 1 and week 3

    The individuals' confidence in their capacity to act in the ways necessary to reach specific goals will be assessed with the Bäbler, Schwarzar, and Jerusalem self-efficacy scale.

  6. Health literacy as assessed by the health literacy questionnaire 16-item, European Health Literacy Survey Questionnaire (HLS-EU-Q16)

    Time frame: Week 1 and week 3

    The degree to which individuals have the ability to find, understand, and use information and services to inform health-related decisions and actions for themselves and others. It will be assessed with the health literacy questionnaire 16-item, European Health Literacy Survey Questionnaire (HLS-EU-Q16)

  7. Knowledge about ADHD as assessed by an ad hoc test

    Time frame: Week 1 and week 3

    Knowledge about ADHD will be assessed by means of an ad hoc test containing 15 statements and the patient/parent will indicate whether they are true or false. The total score ranges 0-15 with higher score denoting a better outcome.

  8. Treatment prescribed

    Time frame: Week 1

    This is a qualitative outcome corresponding to the pharmacological or non-pharmacological treatment prescribed by the clinician, therfore it has no units nor range.

  9. Patient satisfaction with the educational material as assessed by a 5-point Likert scale

    Time frame: Week 1

    Patients will be asked to rate their satisfaction with the educational material using a 5-point Likert scale. The total score ranges 1-5 with higher score denoting a better outcome.

  10. Patient satisfaction with the decision-making process as assessed by a 5-point Likert scale

    Time frame: Week 1

    Patients will be asked to rate their satisfaction with the decision-making process using a 5-point Likert scale. The total score ranges 1-5 with higher score denoting a better outcome.

  11. Perceived usefulness of the clinical recommendations as assessed by a 5-point Likert scale

    Time frame: Week 1

    Clinicians will be asked to rate the degree to which they preceive TDApp2 treatment recommendations useful using a 5-point Likert scale. The total score ranges 1-5 with higher score denoting a better outcome.

  12. Adverse events

    Time frame: Weeks 3 and 6

    Adverse events occured during the study

  13. Patient perceived satisfaction with the treatment as assessed by a 5-point Likert scale

    Time frame: Week 6

    Patient satisfaction with the treatment using a 5-point Likert scale. The total score ranges 1-5 with higher score denoting a better outcome.

  14. Clinicians satisfaction with the treatment recommendations formulated by TDApp2 as assessed by a 5-point Likert scale

    Time frame: Week 6

    Clinician satisfaction (Clinicians fulfilment of their expectations or needs derived from the treatment recommendations formulated by TDApp2) with the treatment using a 5-point Likert scale.The total score ranges 1-5 with higher score denoting a better outcome.

Sponsors and collaborators

Lead sponsor

Universitat de Girona

Other

Collaborators

  • Institut d'Assistència Sanitària

Registry information

Official study title

Assesment of TDApp2 an eHelath Tool to Make Pharmacologic and Non-pharmacologic Treatment Recommendations for Patients With ADHD

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 15, 2022
Registry last updated
Jul 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.